Govorestat
Govorestat (AT-007) is an aldose reductase inhibitor and experimental drug to treat galactosemia and sorbitol dehydrogenase deficiency. After a report circulating on the internet accused the developer Applied Therapeutics of cutting corners in its studies of the drug, the FDA put a hold on it in 2020. Applied Therapeutics said that the report was a fraudulent attempt to manipulate its stock price. Society and culture Legal status In December 2024, Advanz Pharma Limited withdrew its application for a marketing authorization of Nugalviq for the treatment of classic galactosaemia, a condition where the body cannot break down a sugar called galactose. References

{{Authority control Aldose reductase inhibitors Trifluoromethyl compounds Benzothiazoles Carboxylic acids Pyridazines Thienopyridines ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]